Motilal Oswal: Ajanta Pharma Delivers Superior Performance In Q1 Driven By U.S. And Asia Businesses

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.Ajanta Pharma Ltd. delivered superior Q1 FY21 performance in the U.S./Asia.Revenues were up 9.2% YoY to Rs 6.7 billion (versus estimate Rs 6.4 billion), led by growth in exports (19% YoY to Rs 4.8 billion), U.S. generic sales (46% YoY to Rs 1.5 billion; 22% of sales) and Asia sales (27.8% YoY to Rs 1.6 billion; 24% of sales).Africa sales dipped 2% YoY to Rs 1.7 billion (25% of sales), led by 23% YoY decline in Institutional sales to Rs 620 million.Domestic formulation sales declined 10% YoY to Rs 1.78 billion (approximately 26% of sales).Gross margin expanded 40 basis point YoY to 77.1%. Ebitda margin expanded at higher rate of 590 basis point YoY with superior product mix and controlled opex.As percentage of sales, other expense was down 650 basis point YoY, which was marginally off-set by 100 basis point rise in employee cost..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Motilal Oswal: Ajanta Pharma Delivers Superior Performance In Q1 Driven By U.S. And Asia Businesses

Motilal Oswal: Ajanta Pharma Delivers Superior Performance In Q1 Driven By U.S. And Asia Businesses

Choose a plan